## In the Specification:

Please replace the paragraph beginning at line number 5 on page 1 with the following rewritten line:

This application is a continuation-in-part <u>and claims</u> <u>benefit</u> of Serial No. 09/875,392 (pending), now U.S. Patent No. 6,783,979, issued August 31, 2004.

Please replace paragraph beginning at line number 18 on page 9 with the following rewritten line:

Figure 10A-G 10A-H: functional expression of HCN1 and HCN2 channels with and without minK and MiRPl in Xenopus oocytes. The holding potential is -35mV, and the voltage increment is always 10mV. A: 5ng HCN1 cRNA injection and test pulses 3-seconds long from -65mV to a maximum voltage of -115mV. B: 5ng HCN1 plus 0.2ng minK injection with test pulses 3-seconds long from a minimum voltage of -55mV to a maximum voltage of -115mV. C: 5ng HCN1 plus 0.2ng MiRP1 injection with test pulses 3-seconds long from -55mV to -5ng HCN2 cRNA injection with test pulses 8seconds long from -55mV to -95mV. E: 5ng HCN2 plus 0.2ng minK injection with test pulses 8-seconds long from -65mV to -105mV. F: 5ng HCN2 plus 0.2ng MiRP1 injection with test pulses 8-seconds long from -55mV to -95mV. G: the maximum conductance of the tail current obtained by dividing its potential. amplitude by the driving force at that